ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of ALK Ragweed Tablet

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00330083
Recruitment Status : Completed
First Posted : May 25, 2006
Last Update Posted : September 21, 2007
Sponsor:
Information provided by:
ALK-Abelló A/S

May 23, 2006
May 25, 2006
September 21, 2007
May 2006
Not Provided
Assessment of safety by recording of adverse events
Same as current
Complete list of historical versions of study NCT00330083 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety of ALK Ragweed Tablet
A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Allergy
Biological: ALK Ragweed Tablet
Not Provided
Christensen LH, Ipsen H, Nolte H, Maloney J, Nelson HS, Weber R, Lund K. Short ragweeds is highly cross-reactive with other ragweeds. Ann Allergy Asthma Immunol. 2015 Dec;115(6):490-495.e1. doi: 10.1016/j.anai.2015.09.016. Epub 2015 Oct 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
Same as current
Not Provided
Not Provided

Inclusion Criteria:

  • Ragweed pollen induced rhinoconjunctivitis
  • Adults of either sex (18-50 years of age)
  • Positive skin prick test to ragweed

Exclusion Criteria:

  • Previous treatment with immunotherapy
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00330083
RT-01
Not Provided
Not Provided
Not Provided
Not Provided
ALK-Abelló A/S
Not Provided
Principal Investigator: George J. Atiee, MD Healthcare Discoveries Inc.
ALK-Abelló A/S
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP